Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	inclusion criteria: * diagnosis of cll was according to the iwcll criteria * all patients received two 30-μg doses of bnt162b2, administered intramuscularly 3 weeks apart. (pfizer).	inclusion criteria: * diagnosis of cll was according to the iwcll criteria * all patients received two 30-μg doses of bnt162b2, administered intramuscularly 3 weeks apart. (pfizer).
April 29, 2021, 10:18 a.m.	usa	inclusion criteria: - diagnosis of cll was according to the iwcll criteria - all patients received two 30-μg doses of bnt162b2, administered intramuscularly 3 weeks apart. (pfizer).	inclusion criteria: - diagnosis of cll was according to the iwcll criteria - all patients received two 30-μg doses of bnt162b2, administered intramuscularly 3 weeks apart. (pfizer).